Asianol Biotech Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 4.95 Cr
as on 23-10-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.90 M
as on 23-10-2024
- Revenue 6.71%
(FY 2023)
- Profit -30.94%
(FY 2023)
- Ebitda -41.67%
(FY 2023)
- Net Worth 19.16%
(FY 2023)
- Total Assets 17.98%
(FY 2023)
About Asianol Biotech
The Corporate was formerly known as Asianol Specialty Chemicals Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.95 Cr.
The company currently has active open charges totaling ₹6.90 M.
Gulshan Sachdev, Sheo Kajaria, and Vivek Kajaria serve as directors at the Company.
- CIN/LLPIN
U24299WB2005PTC103411
- Company No.
103411
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 May 2005
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Asianol Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gulshan Sachdev  | Managing Director | 27-May-2005 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vivek Kajaria | Director | 20-Aug-2018 | Current |
| Sheo Kajaria | Director | 27-May-2005 | Current |
Financial Performance and Corporate Structure Insights of Asianol Biotech.
Asianol Biotech Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.71% increase. The company also saw a substantial fall in profitability, with a 30.94% decrease in profit. The company's net worth Soared by an impressive increase of 19.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Asianol Biotech?
In 2023, Asianol Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Super Diamond Nirman Private LimitedActive 20 years 5 monthsSheo Kajaria and Vivek Kajaria are mutual person
Aarmaan Property Developers LlpActive 2 years 10 monthsSheo Kajaria and Vivek Kajaria are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Jun 2022 | ₹6.90 M | Open |
How Many Employees Work at Asianol Biotech?
Asianol Biotech has a workforce of 54 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Asianol Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Asianol Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
